drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
Autologous T cells engineered to express a chimeric antigen receptor targeting CD5, enabling HLA-independent recognition and killing of CD5+ T-ALL cells via CD3ζ/costimulatory signaling, leading to T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD5-specific chimeric antigen receptor bind CD5 on target cells in an HLA-independent manner; CAR signaling via CD3ζ and costimulatory domains activates the T cells, driving proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CD5+ cells (including malignant T-ALL cells).
drug_name
CD5 CAR T-cells
nct_id_drug_ref
NCT06633354